Medications That Cause Gynecomastia

When a man with no obvious hormonal disease develops new breast tissue, his medicine cabinet is the first place to look. Medication-induced gynecomastia is among the most common identifiable causes in adult men — and the most actionable, because sometimes the fix is a prescription change rather than an operation. Sometimes. The qualifier is the fibrosis clock, and it is the most important concept on this page.

Four mechanisms, one result

Every causative drug works through at least one of these routes:

• Oestrogenic activity — the drug or its metabolites stimulate breast tissue directly
• Androgen-receptor blockade — testosterone circulates but cannot act, shifting the effective balance toward oestrogen
• Testosterone suppression — production falls, and the oestrogen/androgen ratio rises
• Prolactin elevation — raised prolactin alters the hormonal axis and stimulates breast tissue

The list, by class

Highest-association drugs

• Spironolactone — diuretic with direct anti-androgen and oestrogenic effects; the classic offender. (Eplerenone, a same-class alternative, largely lacks this effect — a conversation worth having with the prescriber)
• Anti-androgens for prostate cancer — bicalutamide and class relatives; gynecomastia rates are high enough that preventive strategies are sometimes used alongside
• GnRH agonists / androgen-deprivation therapy — profound testosterone suppression
• Exogenous hormones — anabolic steroids and SARMs via aromatisation (the dedicated guide), oestrogen exposure, and poorly supervised testosterone therapy

Moderate association

• 5-alpha-reductase inhibitors — finasteride and dutasteride (hair loss, prostate); a small but real and much-searched risk
• Risperidone and other prolactin-raising antipsychotics; metoclopramide shares the prolactin mechanism
• Ketoconazole (systemic antifungal) — testosterone synthesis inhibition
• Cimetidine — anti-androgenic H2 blocker (modern alternatives largely lack the effect)
• Some HIV-era antiretrovirals, particularly older regimens

Reported, weaker or inconsistent association

• Calcium-channel blockers; ACE inhibitors (rarely); digoxin; amiodarone
• Tricyclic antidepressants; some SSRIs (rare)
• Opioids in chronic use — via testosterone suppression
• Highly active substances outside prescription medicine — alcohol in chronic excess and others, covered in the lifestyle substances guide

The fibrosis clock: why timing decides everything

Drug-stimulated gland passes through the same two phases as any gynecomastia. In the early proliferative phase — roughly the first 6–12 months, often tender — tissue can regress if the stimulus is removed, and tamoxifen has a possible role per the comparison guide. After that, fibrosis: the tissue scars into a permanent disc that no longer cares whether the offending drug continues. Stopping the medication then still matters for preventing progression — but the established disc only leaves surgically.

How this changes surgical planning

• Identify the drug first — a careful medication history is part of every evaluation, alongside the hormonal workup where indicated
• Stabilise before operating — where the medication can be switched, surgery follows the switch; operating under ongoing stimulation invites recurrence of whatever remnant remains
• Where the drug must continue — prostate cancer therapy being the clearest case — surgery proceeds with that reality priced in: thorough gland excision and frank counselling about the remnant

The operation itself follows standard technique selection by Simon grade, and recovery follows the usual protocol.

Frequently asked questions

Assoc. Prof. Dr. Ayhan Işık Erdal, MD, FACS, FEBOPRAS

Double board-certified plastic surgeon · 30+ peer-reviewed publications · Memorial Sloan Kettering & Ghent University Hospital trained · ISAPS World Congress 2023 Gold & Bronze Awards